Insider buying last 90 days
No open-market insider purchases were filed for MDT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MDT insider filing, plotted on the chart in Gekko.Open MDT in Gekko
NYSE: MDT
Medtronic (MDT) Stock Analysis & Forecast
Nov 4 close
$104.96+6.08 (+6.1%)
Gekko Brief
AI summaryNov 4 closeMedtronic surged 4.6% in a single session to close at $104.81, climbing from an opening price of $100.23 and adding roughly $6 billion to its market capitalization, with the stock later closing at $104.96. The move follows positive primary endpoint results from the SPYRAL AFFIRM post-approval study, showing statistically significant blood pressure reductions at six months with the Symplicity Spyral renal denervation system, achieved without increased antihypertensive medication use. The company also announced a new educational partnership with the Michael J. Fox Foundation on deep brain stimulation, and confirmed it will report fiscal 2027 second-quarter results on 24 November 2026.
The close of $104.96 sits above both the 50-day average of $92.22 and the 200-day average of $88.21, with the stock up 20.5% over one month and 35.3% over six months, near its 52-week high of $106.33. The GekkoIndex reads 46.6, placing MDT in the Neutral zone. Price remains 16% below Gekko Fair Value of $125.
Earnings for the most recent quarter, reported 1 September, showed EPS of $1.45 against an estimate of $1.39, with an average absolute reaction of 4.4% across the last 8 quarters. The next report falls on 17 November, 12 days out, inside a typical 20-day holding window. Congressional activity in the last 90 days shows 1 buy and 0 sells. Seasonality over 5 years shows a 0.1% average 20-day return from this point, rising in 2 of those years.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Medtronic price vs fair value
Close $104.96200-day averageGekko Fair Value $125.00
Medtronic quick facts
- Market cap
- $134.3B
- P/E ratio
- 23.7
- Forward P/E
- 16.1
- EPS, TTM
- $4.19
- Revenue, TTM
- $37.54B
- Profit margin
- 13.9%
- Dividend yield
- 2.95%
- Beta
- 0.57
- Volume
- 11.54M avg 22.28M
- 1-year return
- +16.4%
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±4.4%
- 50-day average
- $92.22
- 200-day average
- $88.21
- Next earnings
- Nov 17 before open
- Shares outstanding
- 1.28B
Medtronic swing-trade checklist
Medtronic scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $104.96 is above the 50-day ($92.22) and 200-day ($88.21) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
46.6, Neutral
Reading 46.6 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
16.0% below
Price is 16% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings riskheadwind
Reports in 12 days
Reports on Nov 17, 2026, 12 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+0.1% on average
From this point in the calendar, the next 20 trading days averaged +0.1% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Medtronic stock chart and price history
Medtronic closed at $104.96 on Nov 4, 2026, +16.4% over the past year, inside a 52-week range of $73.31 to $106.33.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +20.5%
- 3 months
- +22.2%
- 6 months
- +35.3%
- 1 year
- +16.4%
The full MDT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MDT in Gekko
Follow Medtronic through every session
Put MDT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MDT in GekkoFree for 7 days. No credit card required.
About Medtronic
Medtronic designs, manufactures and supplies device-based medical therapies used by hospitals, clinicians and patients worldwide. Its work is best known in areas such as heart rhythm devices, surgical tools and diabetes management technology, covering everything from implantable pacemakers to insulin pumps.
The company organizes its work into several portfolios. One covers cardiovascular care, including devices for heart rhythm, structural heart repair and coronary procedures. Another supplies surgical instruments, robotic-assisted platforms and equipment for areas such as hernia repair, lung treatment and patient monitoring. A further portfolio serves specialists like neurosurgeons and pain management doctors with imaging and spinal guidance tools, while a separate unit focuses on diabetes care, offering insulin pumps, glucose monitors and connected insulin pens. Customers span healthcare systems, physicians and patients across many medical fields.
Founded in 1949, Medtronic is headquartered in Dublin, Ireland. Its shares are listed on the NYSE under the ticker MDT.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- medtronic.com
Medtronic GekkoIndex: the smart money zone
Medtronic’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.6, in the Neutral zone, down 7.1 points over five sessions.
46.6Neutral
Down 7.1 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 37 | +1.1% | +4.8% | ||
| Accumulation | 242 | +0.1% | +0.2% | ||
| Neutral (current zone) | 398 | +0.1% | +0.2% | ||
| Distribution | 19 | −0.5% | −2.4% | ||
| Selling | 1 | Too few readings yet | |||
Average MDT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the MDT price, zone by zone.Track MDT in Gekko
Is Medtronic stock overvalued? Gekko Fair Value
Medtronic trades 16.0% below Gekko Fair Value of $125.00, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Medtronic shares are worth, recalculated every trading day.
$125.00
Gekko Fair Value, Nov 4, 2026
16.0% Undervalued
At the end of Aug 2026 the price was 30.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open MDT in Gekko
Medtronic insider and Congress trading
No open-market insider purchases were filed for Medtronic, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 11 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Medtronic has been buying back its own shares.
- Bought back, quarter ended Jul 31, 2026
- $267.0M
- As a share of market cap
- 0.20%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold MDT.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Medtronic earnings: next date and track record
Medtronic reports on Nov 17, 2026, before the open (12 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 17, 2026
Expected before the open, 12 days away
- EPS estimate
- $1.33
- Revenue estimate
- $9.48B
7 of 8reports beat the EPS estimate
±4.4%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Sep 1, 2026 AI summary
- What they said
- MDT reported Q1 fiscal '27 revenue of $9.8 billion with adjusted EPS of $1.45, both exceeding expectations. Organic revenue growth was 13.7%, driven by CRM (+15%), Cranial & Spinal Technologies (+13%), and Surgical (+9%). Key growth drivers included EV-ICD, Micra, OmniaSecure, the AiBLE ecosystem, Stealth AXiS platform, and Cardiac Ablation Solutions. Recent acquisitions also contributed to reported growth.
- Guidance
- Management reaffirmed confidence in achieving fiscal '27 targets, citing healthy underlying markets and multiple scaling growth platforms. The 53-week fiscal year includes an extra week in Q1, which benefited reported results.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Sep 1, 2026 | $1.45 est $1.39 | $9.76B est $9.55B | +1.7% |
| Jun 3, 2026 | $1.55 est $1.56 | $9.81B est $9.62B | +11.1% |
| Feb 17, 2026 | $1.36 est $1.33 | — | −1.0% |
| Nov 18, 2025 | $1.36 est $1.31 | $8.96B est $8.87B | +4.2% |
| Aug 19, 2025 | $1.26 est $1.23 | $8.58B est $8.38B | +0.4% |
| May 21, 2025 | $1.62 est $1.58 | $8.93B est $8.82B | −6.3% |
| Feb 18, 2025 | $1.39 est $1.36 | $8.29B est $8.33B | −6.3% |
| Nov 19, 2024 | $1.26 est $1.25 | $8.40B est $8.27B | −4.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Medtronic stock forecast and analyst price targets
Analysts’ average 12-month price target for Medtronic is $104.62, −0.3% from the last close, from 19 firms rating the stock in the last 90 days.
$104.62consensus 12-month target, −0.3% from the last close
Now $104.96Avg $104.62
Low $85High $118
Each firm’s latest rating in the last 90 days: 19 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 30 | Bank of America Securities | $110 | +4.8% |
| Oct 22 | Piper Sandler | $85 | −19.0% |
| Oct 22 | Bank of America Securities | $110 | +4.8% |
| Oct 16 | J.P. Morgan | — | — |
| Oct 14 | Piper Sandler | $85 | −19.0% |
+0.2%average 20-day move after past Neutral readings
+0.1%average move over the next 20 trading days in the last 5 years
±2.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Medtronic seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Medtronic averaged +0.1% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.1% | 1 of 5 |
| Next 10 trading days | +1.2% | 2 of 5 |
| Next 15 trading days | +0.7% | 2 of 5 |
| Next 20 trading days | +0.1% | 2 of 5 |
| Next 30 trading days | −2.2% | 2 of 5 |
For scale, MDT’s typical 20-trading-day move in either direction is about 4.4%.
Medtronic market cap and key statistics
Medtronic’s market cap is $134.3B, with a P/E ratio of 23.7 and revenue of $37.54B over the last twelve months.
Valuation
- Market cap
- $134.3B
- P/E ratio
- 23.7
- Forward P/E
- 16.1
- EPS, TTM
- $4.19
- Gekko Fair Value
- $125.00
Trading
- Volume
- 11.54M
- Avg volume, 20 days
- 22.28M
- 52-week high
- $106.33
- 52-week low
- $73.31
- Shares outstanding
- 1.28B
Financials
- Revenue, TTM
- $37.54B
- Profit margin
- 13.9%
- Return on equity
- 10.6%
- Quarterly earnings growth, YoY
- +40.7%
Risk and income
- Beta
- 0.57
- Typical daily move
- ±2.4%
- Typical 20-day move
- ±4.4%
- Dividend yield
- 2.95%
Medtronic stock news this week
Coverage of Medtronic this week reads positive: 13 positive, 7 neutral and 0 negative headlines.
- Medtronic (MDT) president Marinaro received 6,547 sharesQuantisnow, Nov 4
- A 6,547-unit stock grant to Medtronic (MDT) President Michael Marinaro vests August 3, 2029.Stock Titan, Nov 4
- Medtronic to announce financial results for its second quarter of fiscal year 2027Medtronic, Nov 4
- Medtronic Surges 4.6% in a Single Session to $104.8124/7 Wall St., Nov 4
- Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson's Understand Deep Brain StimulationMorningstar, Nov 4
- Medtronic and Michael J. Fox Foundation Partner to Help More People with Parkinson's Understand Deep Brain StimulationPR Newswire, Nov 4
Medtronic peers
Medtronic’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| SYKStryker | Distribution | 6.5% above |
| BSXBoston Scientific | Neutral | 26.8% below |
A peer links to its own page where one exists.
Medtronic stock FAQ
What is Medtronic’s market cap?
Medtronic’s market cap is $134.3B at the Nov 4, 2026 close of $104.96, with 1.28B shares outstanding. The shares trade on a P/E ratio of 23.7.
What is the Medtronic stock forecast?
The consensus analyst 12-month price target for Medtronic is $104.62, −0.3% from the last close. Of the 19 firms that rated the stock in the last 90 days, 10 rate it a buy, 9 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Medtronic stock overvalued or undervalued?
On Gekko’s estimate Medtronic is undervalued: the Nov 4, 2026 close of $104.96 is 16.0% below Gekko Fair Value of $125.00. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Medtronic report earnings next?
Medtronic is expected to report on Nov 17, 2026, before the market opens (12 days away). Analysts expect earnings of $1.33 per share on revenue of $9.48B. Medtronic beat the earnings estimate in 7 of its last 8 reports, moving 4.4% on average across the report.
What is Medtronic’s 52-week high and low?
Medtronic’s 52-week high is $106.33 and its 52-week low is $73.31; it closed at $104.96 on Nov 4, 2026, +16.4% over the past year. Over the last five years the shares peaked at $124.63 on Nov 5, 2021.
Is Medtronic stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, fair value and smart money), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Medtronic the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.